Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): A randomized controlled trial

Chest

Volumn 142, Issue 6, 2012, Pages 1383-1390

  Tapson, Victor F ^a   Torres, Fernando ^b   Kermeen, Fiona ^c   Keogh, Anne M ^d   Allen, Roblee P ^e   Frantz, Robert P ^f   Badesch, David B ^g   Frost, Adaani E ^h   Shapiro, Shelley M ⁱ   Laliberte, Kevin ^j   Sigman, Jeffrey ^j   Arneson, Carl ^j   Galiè, Nazzareno ^k  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MAYO CLINIC   (United States)

^g UNIVERSITY OF COLORADO   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j UNITED THERAPEUTICS CORPORATION   (United States)

^k Institute of Cardiology   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN RECEPTOR ANTAGONIST; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; TREPROSTINIL;

ADOLESCENT; ADULT; AGED; ARM PAIN; ARTHRALGIA; ARTICLE; BORG DYSPNEA SCORE; CONTROLLED STUDY; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA FATIGUE INDEX SCORE; EVENING DOSAGE; EXERCISE; FATIGUE; FEMALE; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; JAW PAIN; LEG PAIN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; MYALGIA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PAIN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED RELEASE FORMULATION; THORAX PAIN; TREATMENT OUTCOME; VOMITING; WALKING;

EID: 84866515810     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.11-2212     Document Type: Article

References (32)

1. McLaughlin VV, Archer SL, Badesch DB, et al American College of Cardiology Foundation Task Force on Expert Consensus Documents; American Heart Association; American College of Chest Physicians; American Thoracic Society, Inc; Pulmonary Hypertension Association. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. J Am Coll Cardiol. 2009;53(17):1573-1619.
2. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351(14):1425-1436.
3. Barst RJ, Rubin LJ, Long WA, et al The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334(5):296-302.
4. Simonneau G, Barst RJ, Galiè N, et al Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165(6):800-804. (Pubitemid 34229650)
5. Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest. 2006;129(3):683-688.
6. McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol. 2010;55(18):1915-1922.
7. Olschewski H, Simonneau G, Galiè N, et al Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347(5):322-329. (Pubitemid 34815354)
8. Galiè N, Brundage BH, Ghofrani HA, et al Pulmonary Arterial Hypertension and Response to Tadalafil (PHIRST) Study Group. Tadalafil therapy for pulmonary arterial hypertension [published correction appears in Circulation. 2011;124(10):e279. Dosage error in article text.]. Circulation. 2009;119(22):2894-2903.
9. Galiè N, Ghofrani HA, Torbicki A, et al Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353(20):2148-2157. (Pubitemid 41653106)
10. Galiè N, Olschewski H, Oudiz RJ, et al Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117(23):3010- 3019.
11. Rubin LJ, Badesch DB, Barst RJ, et al; for the Bosentan Randomized Trial of Endothelin Antagonist Therapy Study Group. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346(12):896-903. (Pubitemid 34984638)
12. Galiè N, Humbert M, Vachiéry JL, et al Arterial Pulmonary Hypertension and Beraprost European (ALPHABET) Study Group. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39(9):1496-1502.
13. Yap RL, Mermel LA. Micrococcus infection in patients receiving epoprostenol by continuous infusion. Eur J Clin Microbiol Infect Dis. 2003;22(11):704-705. (Pubitemid 37491628)
14. Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest. 2004;126(1):90-94. (Pubitemid 38943122)
15. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2010.
16. Flolan (epoprostenol sodium) for injection [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; 2011.
17. Rubenfire M, McLaughlin VV, Allen RP, et al. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial. Chest. 2007;132(3):757-763.
18. Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med. 2005;172(12):1586-1589. (Pubitemid 43076550)
19. Hiremath J, Thanikachalam S, Parikh K, et al TRUST Study Group. Exercise improvement and plasma biomarker changes with intravenous treprostinil therapy for pulmonary arterial hypertension: a placebo-controlled trial. J Heart Lung Transplant. 2010;29(2):137-149.
20. White RJ, Allen R, Torres F, et al. Sustained plasma concentrations of treprostinil following chronic dosing of oral treprostinil in patients with pulmonary arterial hypertension. Poster presented at: American Thoracic Society International Conference; May 15-20, 2009; San Deigo, CA.
21. Wade M, Baker FJ, Roscigno R, DellaMaestra W, Hunt TL, Lai AA. Absolute bioavailability and pharmacokinetics of treprostinil sodium administered by acute subcutaneous infusion. J Clin Pharmacol. 2004;44(1):83-88. (Pubitemid 38005097)
22. Gotzkowsky SK, Dingemanse J, Lai A, Mottola D, Laliberte K. Lack of a pharmacokinetic interaction between oral treprostinil and bosentan in healthy adult volunteers. J Clin Pharmacol. 2010;50(7):829-834.
23. Rollins K, Peterson L, Laliberte K, Gotzkowsky SK, Wade M, Mottola D. Overview of the drug-drug interaction potential with treprostinil. Poster presented at: American Tho racic Society International Conference; May 15-20, 2009; San Deigo, CA.
24. Feinstein AR, Fisher MB, Pigeon JG. Changes in dyspnea-fatigue ratings as indicators of quality of life in the treatment of congestive heart failure. Am J Cardiol. 1989;64(1):50-55. (Pubitemid 19166208)
25. Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;28(4):691-694. (Pubitemid 46331988)
26. McLaughlin VV, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174(11):1257-1263. (Pubitemid 44924827)
27. Simonneau G, Rubin LJ, Galiè N, et al PACES Study Group. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. 2008;149(8):521-530.
28. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136(7):515-522. (Pubitemid 34252285)
29. Badesch DB, Raskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest. 2010;137(2):376-387.
30. Provencher S, Sitbon O, Humbert M, Cabrol S, Jaïs X, Simonneau G. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J. 2006;27(5):589-595.
31. McLaughlin V, Langer A, Dragomir A, et al. Treatment of pulmonary arterial hypertension (PAH): data from the Quality Enhancement Research Initiative [Abstract]. Am J Respir Crit Care Med. 2009;179:A1043.
32. Tankersley MA, D'Albini LD, Ozanich AN, Whitman AJ. A 36-month survival analysis of patients beginning oral PAH monotherapy: an indication for escalation of therapy? Poster presented at: Pulmonary Hypertension Association 8th International Pulmonary Hypertension Conference and Scientific Sessions; June 20-22, 2008; Houston, TX.